Proof of principle for the potential of such intervention is shown by amphotericin B, a commonly used treatment for systemic mycoses, which enhances the interaction between HIF-1α C-terminal TAD and FIH-1, thereby blocking p300 recruitment and suppressing hypoxia-induced erythropoietin production [42]. The gene discussed is EPO; the disease is opportunistic mycosis.